Fierce Biotech News & Reports

ASCO: Lilly's faith in Kelonia rewarded with ‘nutty’ CAR-T data

Kelonia shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag Lilly recently paid for the biotech.

Darren Incorvaia May 31, 2026 8:00am

Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome

Jun 1, 2026 3:52am

Entry Japan with Clarity Execute with Confidence

PATH-Solution

Brought to you by Alfresa Holdings Corporation

Fierce Pharma

Akeso's 34% overall survival win comes with caveats

May 31, 2026 8:00am

ASCO: RevMed confident in RAS leadership as rivals square up

May 31, 2026 8:00am

Agios signs $165M deal for blood disorder drug that failed study

Jun 1, 2026 9:26am

More News

Rallybio swerves past Candid pothole to land deal with Avenzo

Jun 1, 2026 9:09am

Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit

Jun 1, 2026 8:31am

Lilly locks in vague, 5-program pact with Haisco worth up to $3B

Jun 1, 2026 7:26am

ASCO: BioNTech/BMS, Pfizer split on bispecific approach in NSCLC

May 30, 2026 3:30pm

See more stories